Sunday, July 3, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home Coronavirus

Vaccine effectiveness against COVID-19 severity in the elderly

by Medical Finance
in Coronavirus
Study: High vaccine effectiveness against severe Covid-19 in the elderly in Finland before and after the emergence of Omicron. Image Credit: Rido/Shutterstock
9
SHARES
100
VIEWS
Share on FacebookShare on Twitter

A recent study posted to the medRxiv* pre-print server assessed vaccine effectiveness (VE) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in elderly patients before and after the spread of the SARS-CoV-2 Omicron variant of concern (VOC). 

Study: High vaccine effectiveness against severe Covid-19 in the elderly in Finland before and after the emergence of Omicron. Image Credit: Rido/Shutterstock
Study: High vaccine effectiveness against severe Covid-19 in the elderly in Finland before and after the emergence of Omicron. Image Credit: Rido/Shutterstock

SARS-CoV-2 vaccines have played an instrumental role in curbing the impact of the coronavirus disease 2019 (COVID-19) pandemic. However, with the emergence of novel SARS-CoV-2 VOCs, VE against infections caused by the VOCs requires extensive research.

About the study

The present study estimated the VE of SARS-CoV-2 vaccines against disease severity, related hospitalizations, and intensive care unit (ICU) admissions in elderly COVID-19 patients in Finland after two and three vaccine doses. The study also assessed the impact of the SARS-CoV-2 Omicron VOC infection on elderly patients.

The study population included persons aged 70 years and more while individual-level demographic data were obtained from the population information system in Finland. Data like age, gender, residence, hospital residency, influenza vaccination, time spent hospitalized from 2015 to 2019, and comorbidities were also collected.

The team evaluated the differences between the three approved vaccine brands, namely Spikevax, Vaxzevria, and Comirnaty, and the number of doses administered of each vaccine. The study also considered the time passed since the vaccination into specific time points, for example, 21 and 84 days post the first dose, 14, 91, and 181 days post the second dose, and 14 and 61 days post the third dose.

The primary outcome of this study was the duration between COVID-19-related hospitalization and a SARS-CoV-2-positive polymerase chain reaction (PCR) test. COVID-19-related hospitalizations were defined as patient admission with the primary diagnosis of COVID-19, acute respiratory tract infections, or severe complications of lower respiratory tract infections. A timely association of hospitalization with COVID-19 infection occurred only if the patient was tested COVID-19-positive 14 days before or seven days after hospital admission.

The secondary outcome was evaluated in terms of COVID-19-related ICU admission which was considered SARS-CoV-2-related if the patient’s physician marked it so, or, if the patient tested COVID-19-positive during the hospital stay. ICU admissions were identified from patient record data obtained from the Finnish intensive care consortium’s quality register for intensive care.   

Results

The study results showed that out of the 897,932 individuals eligible for the study, 4% were unvaccinated, 6% were vaccinated with two vaccine doses of Comirnaty, and 66% were vaccinated with three doses of Comirnaty. There was a dosing interval of 84 days between the first and the second dose and 187 days between the second and the third dose.

There were 637 unvaccinated persons among the 1,522 COVID-19 hospitalized patients and 131 unvaccinated individuals among the 234 ICU admissions. Within 14 to 90 days and 91 to 180 days of administration of the second Comirnaty dose, VE of 93% and 87%, respectively, was observed against hospitalization. These values increased to 96% in the 14 to 60 days post third dose vaccination. VE against ICU admission at these time points was higher than that against hospitalization. Also, a VE of 76% against hospitalization was found after two homologous doses of Vaxzevria in the first 91 to 180 days.

A slight decrease in VE as a subject to increasing age and the presence of comorbidities was also observed. In individuals aged 70 to 79 years, the VE of Comirnaty after the second dose was 95% in the first 14 to 90 days and 88% in the 91 to 180 days; whereas the VE at the same time points corresponded to 89% and 83%, respectively, for patients aged 80 to 89 years. The presence of predisposed comorbidities lowered the VE from 92% to 83% in the 91 to 180 days post the administration of the second Comirnaty vaccine dose while a reduction from 99% to 95% was found 14 to 60 days after the third Comirnaty dose.

The VE of Comirnaty against COVID-19-related hospitalization in the fourth quarter of 2021 was 90% in the first 14 to 90 days post-second vaccination which increased to 96% in the 14 to 60 days post third vaccination, while the same in the SARS-CoV-2 Omicron-dominated first quarter of 2022 were 91% and 95%, respectively. While in the fourth quarter, no significant difference was found in the VE 14 to 90 days and 91 to 180 days after the second dose, the VE in the first quarter reduced to 76% in the 91 to 180 days post-second dose.    

Conclusion

Overall, the study findings showed that COVID-19 vaccines have provided sufficient protection against COVID-19-related hospitalization and ICU admission in the high-risk elderly population. The team also found evidence for waning VE across the first six months after vaccination with the two-dose series while the third dose significantly improved the VE for at least two to three months post third dose administration.  

*Important notice

medRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Study: Evidence of SARS-CoV-2 Reinfection: Analysis of 35,000 Subjects and Overview of Systematic Reviews. Image Credit: Corona Borealis Studio/Shutterstock

Researchers assess prevalence of SARS-CoV-2 reinfections

by Medical Finance
July 3, 2022
0

In a recent study posted on Preprints with The Lancet*, researchers assessed the prevalence of severe acute respiratory syndrome coronavirus 2...

Study: Brequinar and Dipyridamole in Combination Exhibits Synergistic Antiviral Activity Against SARS-CoV-2 in vitro: Rationale for a host-acting antiviral treatment strategy for COVID-19. Image Credit: MIA Studio/Shutterstock

Study explores broad-spectrum, host-acting antiviral strategy to treat SARS-CoV-2

by Medical Finance
July 3, 2022
0

Small molecules with antiviral activity against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can offer therapeutic possibilities for the...

Study: Real-World Evidence of the Neutralizing Monoclonal Antibody Sotrovimab for Preventing Hospitalization and Mortality in COVID-19 Outpatients. Image Credit: joshimerbin/Shutterstock

Sotrovimab found to prevent hospitalization and mortality in COVID-19 outpatients

by Medical Finance
July 3, 2022
0

In a recent study posted to the medRxiv* preprint server, researchers tested the efficacy of sotrovimab, a neutralizing monoclonal antibody...

Study: Vaccine-induced immune thrombotic thrombocytopenia (VITT) is mediated by a stereotyped clonotypic antibody. Image Credit: Corona Borealis Studio/Shutterstock

Molecular signature of highly stereotyped clonotypic anti-PF4 antibodies indicates shared pathways of antibody production in VITT patients

by Medical Finance
July 3, 2022
0

A recent article posted to the medRxiv* preprint server analyzed the antibody (Ab) that mediated the coronavirus disease 2019 (COVID-19) vaccine-induced...

Study: The new normal? Dynamics and scale of the SARS-CoV-2 variant Omicron epidemic in England. Image Credit: DOERS/Shutterstock

The dynamics of the Omicron wave in England

by Medical Finance
July 3, 2022
0

In a recent study posted to the medRxiv* preprint server, researchers investigated the transmission dynamics of severe acute respiratory syndrome...

Study: SARS-CoV-2 hyperimmune globulin for severely immunocompromised patients with COVID-19: a randomised, controlled, double-blind, phase 3 trial. Image Credit: shutter_o/Shutterstock

Efficacy of SARS-CoV-2 hyperimmune globulin in treatment of severely immunocompromised hospitalized COVID-19 patients

by Medical Finance
July 3, 2022
0

In a recent study posted to the medRxiv* preprint server, researchers conducted a controlled, double-blinded Phase III trial to evaluate...

Next Post
Study: Protective Immunity of the Primary SARS-CoV-2 Infection Reduces Disease Severity Post Re-Infection with Delta Variants in Syrian Hamsters. Image Credit: Natalia7/Shutterstock

Study reports reduced disease severity in Syrian hamsters during re-infection with SARS-CoV-2 Delta variant

Study: SARS-CoV-2 genomic surveillance enables the identification of Delta/Omicron co-infections in Argentina. Image Credit: FOTOGRIN/Shutterstock

Study finds co-infected individuals carrying two distinct lineages of SARS-CoV-2 in Argentina

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • ImageForNews 710020 16492965713066489
    Israeli research confirms BNT162b2 booster’s effectiveness
  • 78486183 620x480
    Researchers discover how one type of T cell creates functionally distinct, but genetically identical daughter cells
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply